ASX ANNOUNCEMENT

Actinogen Presentation and Planned Conference Call

Sydney, 15 October 2020. Actinogen Medical ASX: ACW ('ACW' or 'the Company') is pleased to advise that Dr. Bill Ketelbey, CEO and MD of Actinogen, will provide an update on the clinical development plans for Xanamem during a conference call **on Monday, 19 October 2020 at 11:00am (AEDT)**. Dr. Ketelbey will provide an overview of the new indication in Fragile X syndrome, the planned Alzheimer's disease and Fragile X syndrome phase II clinical trials, and the capital raising to support the Alzheimer's trial.

The investor presentation is attached to this announcement and will be available on the webcast.

Participants are invited to register for the webcast using the link below. Upon registration, participants will receive a unique pin granting fast-track access to the conference call. Questions may be submitted prior to the conference call through this facility, and further questions accepted on the day.

Pre-register here: https://s1.c-conf.com/DiamondPass/10010450-pH45r6.html

If you are unable to register for the webcast, please call one of the numbers below prior to the start of the event and quote the following Conference ID: **10010450.**

Australia Local:	02 9007 8048	Singapore Toll Free:	800 101 2702
Australia Toll Free:	1800 908 299	Malaysia Toll Free:	1800 816 441
New Zealand Toll Free:	0800 452 795	Hong Kong Toll Free:	800 968 273
USA / Canada Toll Free:	1 855 624 0077	United Kingdom Toll Free:	0800 051 1453

A recording of the conference call will be uploaded on Actinogen's website when available.

ENDS

Actinogen Medical
Dr. Bill Ketelbey
CEO & Managing Director
P: +61 2 8964 7401
E: bill.ketelbey@actinogen.com.au
@BillKetelbey

Investor Enquiries
Miranda Newnham
Vesparum Capital
P: +61 3 8582 4800
E: actinogen@vesparum.com

Announcement authorised by the Board of Directors of Actinogen Medical

About Actinogen Medical

Actinogen Medical (ASX:ACW) is an ASX-listed biotechnology company developing novel therapies for neurological, psychiatric and metabolic diseases associated with chronically elevated cortisol. The company is currently developing its lead compound, Xanamem, as a promising new therapy for Alzheimer's disease, fragile X syndrome, schizophrenia and diabetes. The cognitive dysfunction, behavioural abnormalities, and neuropsychological burden associated with these conditions is significantly debilitating for patients, and there is a substantial unmet medical need for new and improved treatments.

About Xanamem™

Xanamem's novel mechanism of action works by blocking the production of intracellular cortisol – the stress hormone – through the inhibition of the 11β-HSD1 enzyme in the brain. There is a strong association between persistent stress and the production of excess cortisol that leads to detrimental changes in the brain, affecting memory, cognitive function and behaviour and neuropsychological symptoms. The 11β-HSD1 enzyme is particularly highly concentrated in the hippocampus and frontal cortex, areas of the brain impacted by a number of diseases and disorders, including Alzheimer's disease, fragile X syndrome, schizophrenia, diabetes and other conditions associated with chronically raised cortisol.

The Company's XanaHES Phase I trial exploring the safety and tolerability of Xanamem 20mg once daily in healthy elderly volunteers, confirmed the drug's safety profile with no treatment-related serious adverse events. Additionally, the trial demonstrated that Xanamem produced a statistically significant improvement in cognition over placebo, which, along with other recently generated data, confirms 11β-HSD1 inhibition by Xanamem as a promising potential treatment for cognitive impairment associated with raised cortisol.

The Company plans to initiate Phase II studies of Xanamem in various disease areas in 2021, including MCI due to Alzheimer's disease, and Fragile X Syndrome.

Xanamem is an investigational product and is not approved for use outside of a clinical trial by the FDA or by any global regulatory authority.

Xanamem™ is a trademark of Actinogen Medical.

Disclaimer

This announcement and attachments may contain certain forward-looking statements that are based on subjective estimates and assumptions and relate to circumstances and events that have not taken place and may not take place. Such forward looking statements involve known and unknown risks, uncertainties, and other factors (such as significant business, economic and competitive uncertainties and contingencies and regulatory and clinical development risks and uncertainties) which may cause the actual results or the performance of Actinogen Medical to be materially different from the results or performance expressed or implied by such forward looking statements. Past performance is not a reliable indicator of future performance. There can be no assurance that any forward-looking statements will be realised. Actinogen Medical does not make any representation or give any warranty as to the likelihood of achievement or reasonableness of any forward-looking statements.

Actinogen Medical encourages all current investors to go paperless by registering their details with the designated registry service provider, Link Market Services.

DEAL PRESENTATION

Dr. Bill Ketelbey: CEO & MD

October 2020

Developing novel therapies for cognitive impairment and behavioural symptoms due to raised cortisol in chronic neurological, psychiatric, developmental and metabolic diseases



Actinogen Medical

Executive summary

Developing Xanamem™ for cognitive impairment and behavioural symptoms due to raised cortisol in chronic neurological, psychiatric, developmental and metabolic diseases

Xanamem an oral, brain penetrant, selective and effective 11β-HSD1 inhibitor. Comprehensive analysis of the substantial dataset completed with conclusions to define study parameters for next series of clinical studies

XanaMIA - Phase II study targeting an early stage of Alzheimer's disease characterised as Mild Cognitive Impairment, linking the compelling XanaHES efficacy results with an Alzheimer's population, and targeting a huge commercial opportunity

XanaFX - anxiety, sleep & behavioural problems in Fragile X syndrome selected as new indication. A compelling clinical application to target adolescents with an Orphan Disease. Highlighting the breadth of Xanamem's potential clinical indications

Strong outlook with Actinogen developing plans for multiple clinical trials expected to commence in 1H CY21

Capital raising of around A$10.9 via a oversubscribed A$6.0m Institutional Placement and a 1 for 5 Non Renounceable Entitlement Offer to existing shareholders to raise approximately A$4.9m

Actinogen Medical

AD: Alzheimer's disease

Leveraging development across multiple indications

Xanamem's strategic development across multiple target indications, complementing Alzheimer's disease with Fragile X syndrome selected as a new priority clinical development opportunity

XanaMIA: Phase II trial in MCI due to AD

Alzheimer's disease (AD) remains a focus for Actinogen - leveraging breakthrough XanaHES[3] efficacy results into an AD patient population

XanaMIA - a world-first Phase II trial to demonstrate the safety, tolerability and efficacy of Xanamem 10mg twice daily in patients with mild cognitive impairment (MCI) due to AD

XanaMIA: Funded by capital raise



FXS selected as next clinical development opportunity

Anxiety, sleep, and behavioural problems in Fragile X syndrome selected as Actinogen's next clinical development opportunity

Follows significant clinical interest and an extensive scientific, clinical and commercial review

Potential for Orphan Drug Designation and Rare Paediatric Disease Designation provides attractive regulatory, development and commercial benefits

XanaFX: Funded Phase II trial

Actinogen Medical

1. Cognitive impairment associated with Schizophrenia (CIAS)
2. Cognitive impairment associated with Type 2 Diabetes (CIAD)
3. XanaHES – a phase I clinical study in healthy elderly subjects completed in October 2019, demonstrating robust safety and efficacy with Xanamem 20mg daily for 12 weeks (see slide 11)

Attractive development pipeline

Actinogen is targeting a broad portfolio of clinical indications to assess the efficacy of it's lead drug, Xanamem

Studies	2H CY20	1H CY21	2H CY21	Upcoming catalyst[1]
XanaMIA: *Mild cognitive impairment due to* **Alzheimer's disease**	*Trial planning*	*Phase II trial*		*Trial to commence recruitment in* ***1H CY21*** *Expected completion* ***within 24 months***
XanaFX: *Anxiety, sleep & behavioural problems in* **Fragile X syndrome**	*Trial planning*	*Phase II trial*		*Trial to commence in* ***1H CY21*** *Expected completion* ***within 12 months***
Cognitive impairment in **Schizophrenia / Diabetes**	*Trial planning for Phase II studies*			*Grant funding applications submitted,* ***collaboration and partnership*** *discussions ongoing*

Actinogen Medical

Note: 1. Timetable is dependent on a number of external factors (including COVID-19 restrictions and regulatory approvals)

Xanamem™ – lead compound

Novel Mechanism of Action - designed to inhibit cortisol production in the brain (through inhibition of the 11ß-HSD1 enzyme)



Compelling results from various studies underpin further clinical development

- *Pre-clinical long-term toxicology studies*
- *Phase II trial in Alzheimer's patients (10mg daily)*
- *Phase I Target occupancy & Homogenate binding*
- *Phase I trial in Healthy Elderly Subjects (20mg daily)*
- *Comprehensive dataset analysis*

Actinogen Medical

Key outcomes from Xanamem studies

Xanamem, an oral compound, demonstrated to be an efficacious, safe, brain penetrant, selective and effective 11ß –HSD1 inhibitor producing significant pharmacodynamic effects on cortisol

		Xanamem dose
Cognitive Efficacy	Breakthrough results demonstrate a statistically significant clinical effect in **improving cognition** in healthy elderly patients	*20mg*
Target Occupancy	Confirms **Xanamem works as designed** to penetrate the brain in concentrations that adequately inhibit the activity of 11ß-HSD1 enzyme	*5mg - 30mg*
Cortisol inhibition	**Cortisol inhibition** demonstrated pharmacodynamically in human trials	*10mg & 20mg*
	Statistically significant reduction in serum cortisol in human trial	*20mg*
Safety	**Strong safety profile** demonstrated in human trials	*10mg & 20mg*

Actinogen Medical

Target Occupancy study: positive confirmatory data

Phase I target occupancy study demonstrates that 5mg to 30mg Xanamem dosed for seven days significantly binds to the neuronal 11ß-HSD1 enzyme throughout the brain (32 of 36 patients completed)



50% to 85% occupancy, dependent upon brain region, dosage and study subject[1]

Phase I Target Occupancy supports Xanamem as a potent, orally bioavailable and brain-penetrant 11β-HSD1 inhibitor

Actinogen Medical

1. Study population consisted of ~50% healthy subjects (cognitively normal) and ~50% with Alzheimer's diseas

MCI due to Alzheimer‘s disease



Alzheimer's disease remains a focus

Market dynamics of Alzheimer's disease presents a compelling commercial opportunity for Actinogen

Substantial target market with significant upside[1]

Cognitively normal	*Subjective memory decline*	*Cognitive and functional decline fulfilling Alzheimer's disease (AD)*		
At-risk	**MCI due to AD**	**Mild**	**Moderate**	**Severe**
15.5m[3]-26.9m[4]	**~4.3m**	**~1.7m**	**~2.3m**	**~1.7m**

Upside potential for earlier use

Key focus

>US$13.7bn

Target annual peak sales[2]

Underpinned by favourable market dynamics

Targeting **large addressable** markets (US, EU5[5], JP)

All **currently approved drugs are symptomatic treatments** (that do not affect disease progression) **providing limited benefit**

Treatment **prices are robust** (despite generic competition) – with users paying for modest clinical efficacy

Actinogen Medical

Source: Drugs.com, Biogen, Roche, Datamonitor, Alzheimer's Association, aibl study; Bio-Link
MCI: Mild Cognitive Impairment; AD: Alzheimer's disease 1. Target market statistics expected in 2020, based on the current US treatment landscape. 2. Sales in 2036. Case assumes: (1) Launch: US 2027, EU5, JP and ROW 2028; (2) Penetration: 30% of mild AD and MCI markets in 5 years, sustained for 6 years with patent extension; (3) Pricing: US – US$24/day gross (US$19/day net), ROW: 50% of US price; 3. Biogen 2015 27% >65y/o Aβ+; 4. Raised cortisol in 50%>65y/o (AIBL study, Pietrzak et al., 2017) (5) UK, France, Germany, Italy, Spain

Alzheimer's disease – Mild Cognitive Impairment due to AD

XanaMIA – evaluating Xanamem in patients with Mild Cognitive Impairment (MCI) due to AD (an early stage of the AD spectrum), linking the compelling XanaHES results with an Alzheimer's disease patient population



- MCI due to Alzheimer's **affects ~8% of those over 65 years of age**
- **Conversion rate** to mild Alzheimer's **~10-15% per annum**
- Patients have characteristic **patho-physiological changes of Alzheimer's** (ie. functional impairment)

XanaMIA - Phase II trial to demonstrate Xanamem's pro-cognitive effects in MCI due to AD patients

Actinogen Medical

Significant cognitive efficacy signal achieved

New XanaMIA trial to leverage breakthrough XanaHES results[1] demonstrate robust statistically significant cognitive efficacy improvement in multiple cognition domains – based on Cogstate Cognitive Test Battery

Working memory (One Back Test)

Strongly statistically significant result



Visual attention (Identification Test)

Statistically significant result



Psychomotor function (Detection Test)

Good trend to a positive result



Rapid response, evident by week 4, and sustained response out to end of therapy (wk 12)

Treatment Group
Xanamem 30pts
Placebo 12 pts

Efficacy results reflect high quality and consistent data in a small study population

Notes: All values are the means of observed data. p values were calculated with an ANCOVA (analysis of covariance) model using Baseline values as a covariate.
1. XanaHES results announced to the ASX 1 October 2019

XanaMIA - Phase II clinical trial

XanaMIA: A Phase II trial to demonstrate the safety, tolerability and efficacy of Xanamem 10mg twice daily in patients with MCI due to Alzheimer's disease

Proposed clinical trial design

Study design	▪ Phase II proof-of-concept study; double-blind, placebo-controlled ▪ 24 weeks treatment; clinical sites in Australia ▪ 72 males & females (65-80yrs) with MCI (NIA-AA criteria / CDR 0.5 / compromised memory) due to AD ▪ AD diagnosis confirmed by pathology: CSF Aβ / CSF tau or amyloid PET
Primary endpoints	▪ Safety and tolerability assessment of Xanamem in this population
Secondary endpoints	▪ Improvement in specific domains of attention and memory: Cogstate NTB, RBANS, CDR-SOB ▪ Xanamem PK in plasma and CSF ▪ PD biomarkers, including cortisol and cortisone using 24-hour micro-dialysis and 24-hour salivary sampling
Exploratory endpoints	▪ Improvement in all domains of cognitive assessments (Cogstate NTB, RBANS, CDR-SOB) ▪ Change in CSF and plasma biomarkers: Aβ, tau, NfL, TREM2, GFAP ▪ Change in temporoparietal hypometabolism assessed by FDG-PET ▪ Assessment of sleep and anxiety patterns in correlation with circadian and ultradian rhythms measured via micro-dialysis ▪ Evaluation of change in Instrumental Activities of Daily Living (IADL)

Key milestones

XanaMIA planned to **commence recruitment in 1H CY21**[1]

Expected **completion within 24 months**[1]

Trial to be funded by capital raising

Actinogen Medical

Note: 1. Timing is dependent on a number of external factors (including COVID-19 restrictions and regulatory approvals)

Fragile X syndrome

Fragile X syndrome

Fragile X syndrome is a rare genetic condition with behavioural symptoms (including intense anxiety) and cognitive deficit representing a significant unmet medical need with limited treatment options

FXS is caused by mutations in the Fragile X gene (FMR1) of the X chromosome.

Most common cause of genetically inherited intellectual disability.



Diagnosis typically occurs around 3-5 years of age.

FXS is characterised by a range of developmental problems including learning disabilities, behavioural issues including autism features, cognitive impairment, speech and language deficits, sleep problems, anxiety, and severe difficulties with regulating stress and emotions.

Management of FXS is often complex, with life-long treatment required for patients.

There are no approved drugs to treat Fragile X syndrome.

Actinogen Medical

Research supports Xanamem as a FXS treatment

Medical and scientific research validates cortisol as a therapeutic target in FXS

Raised cortisol associated with stress-induced behavioural problems in FXS

- Biological changes in FXS promotes elevated cortisol in the brain
- Higher salivary cortisol linked to cognitive demands and behavioral problems in FXS
- Elevated baseline cortisol associated with working memory deficits in FXS
- Increased cortisol associated with elevated symptoms of general anxiety and social avoidance in young adult males with FXS

Xanamem safely and effectively inhibits cortisol production

- ✓ Association between persistent stress and production of excess cortisol leading to changes in the brain
- ✓ Actinogen's studies demonstrate cortisol inhibition and cognitive enhancement with Xanamem in human trials
- ✓ Further, recent clinical results confirm that Xanamem works as designed, to penetrate the brain in concentrations that adequately inhibit the activity of the 11ß-HSD1 enzyme

Actinogen Medical

Source: Wisbeck et al. 2000; Hessl et al. 2002; Scherr et al. 2016; Matherly et al. 2018; Lupien et al. 1998, Abdanipour et al. 2015, Roberts et al. 2018

Valuable FXS market opportunity

While FXS is a rare disease, anxiety, sleep, and behavioural symptoms in FXS represent substantial commercial opportunities

Target population	Prevalence
Anxiety, sleep, and behavioural problems in FXS adolescents	*Approx. 1 in 2500-4000 males and 1 in 7000-8000 females (averages to 1/4500)*

Substantial market opportunity[1]

~US$250m

With 14.4% compound annual growth

1. FSX market in 2026. GlobalData analyst report 2018. Projection for 7 major markets: US, France, Germany, Italy, Spain, UK, Japan

Actinogen Medical

Clinical development underpinned by strategic benefits

Xanamem in FXS - attractive regulatory, development, and commercial benefits through potential increased speed to market, reduced costs, and enhanced competitive protection

Benefits provided by Orphan Drug and Rare Paediatric Disease Designation[1,2,3]

- Clinical trials for rare diseases **typically enrol fewer patients**, potentially **decreasing costs and shortening development timelines**
- **Regulatory exclusivity / competitive protection,** with extended period of exclusivity in majority of key markets, including USA, Europe and Japan
- **Increased speed to market** from priority review[2], with potential to receive a second, transferable, **Priority Review Voucher (PRV)**[3] from the FDA (applicable to other indications / drugs or can be sold)
- **Direct commercial incentives,** including tax credits, potential sale of second PRV (approx. US$130m)[3]

Data generated for FXS could be leveraged for other indications, potentially decreasing the time to market for the AD indication; **also presents a significant potential upside with FXS-related conditions (e.g. Autism Spectrum Disorder)**

1. FXS is an orphan disease, whose rarity means that there is potential for novel therapeutics targeting FXS to be granted Orphan Drug Designation; leading to regulatory, development and commercial incentives for drug developers.
2. In the USA, developers of orphan drugs for paediatric indications that have been granted a Rare Paediatric Disease Designation may apply for a Rare Paediatric Disease priority review voucher (PRV) from the FDA.
3. Pending reapproval by US Congress of the Rare Paediatric Disease program

Phase II clinical trial

XanaFX: A Phase II trial to demonstrate the safety and efficacy of Xanamem on anxiety, sleep, and behavioural problems in adolescent males with Fragile X syndrome

Clinical trial design

Study design	▪ Phase II proof-of-concept study ▪ Double-blind, placebo-controlled ▪ Investigator-Initiated Trial, conducted at the Melbourne Children's Trials Centre at Murdoch Children's Research Institute and the Royal Children's Hospital ▪ Planning for ~40 adolescents (12-18yrs) with FXS
Primary endpoints	▪ Safety and tolerability assessments of Xanamem in this population
Secondary endpoints	▪ Efficacy assessment - improvement in anxiety, sleep, behavioural problems, communication, socialisation, and daily living skills

Key upcoming milestones

- Planned FXS clinical trial to **commence in 1H CY21**[1]
- Expected **completion within 12 months**[1]
- Trial **funded**, with grant applications submitted to assist with funding

Actinogen Medical

Note: 1. Timing is dependent on a number of external factors (including COVID-19 restrictions and regulatory approvals)

Outlook



Next steps and key catalysts

Plans for key clinical trials, expected to commence in 1H CY21

- ❑ **Finalise optimal study parameters and trial protocols** (4Q CY20)
- ❑ **Apply for FXS Orphan Drug and Rare Paediatric Disease Designation**
- ❑ **Receive regulatory approval and commence next phase of clinical trials** (1H CY21)
  - ❑ **XanaMIA - MCI due to Alzheimer's disease**
  - ❑ **XanaFX – anxiety, sleep and behavioural problems in FXS**
- ❑ **XanaFX study readout** (12 months from trial commencement)
- ❑ **Submit further grant applications** and explore potential funding opportunities with external partners, including for cognitive impairment in both schizophrenia and diabetes

Actinogen Medical

Note: Timing is dependent on a number of external factors (including COVID-19 restrictions and regulatory approvals)

Disclaimer

This presentation has been prepared by Actinogen Medical Limited. ("Actinogen" or the "Company") based on information available to it as at the date of this presentation. The information in this presentation is provided in summary form and does not contain all information necessary to make an investment decision.

This presentation does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any security in Actinogen, nor does it constitute financial product advice or take into account any individual's investment objectives, taxation situation, financial situation or needs. An investor must not act on the basis of any matter contained in this presentation but must make its own assessment of Actinogen and conduct its own investigations. Before making an investment decision, investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs, and seek legal, taxation and financial advice appropriate to their jurisdiction and circumstances. Actinogen is not licensed to provide financial product advice in respect of its securities or any other financial products. Cooling off rights do not apply to the acquisition of Actinogen securities.

Although reasonable care has been taken to ensure that the facts stated in this presentation are accurate and that the opinions expressed are fair and reasonable, no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, none of Actinogen its officers, directors, employees and agents, nor any other person, accepts any responsibility and liability for the content of this presentation including, without limitation, any liability arising from fault or negligence, for any loss arising from the use of or reliance on any of the information contained in this presentation or otherwise arising in connection with it.

The information presented in this presentation is subject to change without notice and Actinogen does not have any responsibility or obligation to inform you of any matter arising or coming to their notice, after the date of this presentation, which may affect any matter referred to in this presentation.

This presentation is not for general distribution or third party reliance or use.

This presentation contains certain budget information, forecasts and forward looking statements that are based on the Company's management's beliefs, assumptions and expectations and on information currently available to management in respect of which there is **NO guarantee of future performance**. Such budget information, forecasts and forward looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results or performance of Actinogen to be materially different from the results or performance expressed or implied by such forward looking statements. These risks and uncertainties include, but are not limited to the performance of Actinogen in its clinical trials including whether it's technology proves to be a safe and effective treatment, market penetration, competition from any other similar products, intellectual property risks (including securing rights in technology and patents) and global economic conditions. Furthermore, Actinogen's research, product development, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. There is no guarantee that Actinogen will obtain the required approvals, licences and registrations from the relevant authorities in jurisdictions in which it operates. Actinogen or others could identify product and efficacy issues relating to the safety of our technology. Accordingly, all forward looking statements are based on numerous assumptions regarding the Company's present and future business strategies and the political and economic environment in which Actinogen will operate in the future, which are subject to change without notice. Past performance is not necessarily a guide to future performance and no representation or warranty is made as to the likelihood of achievement or reasonableness of any forward looking statements or other forecast. There is no guarantee that Actinogen will achieve its stated objectives/milestones, that any of its forecasts will be met or that forward looking statements will be realised. You are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof, and we do not undertake any obligation to revise and disseminate forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of or non-occurrence of any events.

Neither Actinogen nor any other entity or person in or associated with Actinogen guarantee any return (whether capital or income) or generally the performance of Actinogen or the price at which its securities may trade. Any investment in Actinogen is subject to investment risks including the possibility of loss of capital invested and no return of income or payment of any dividends.

To the maximum extent permitted at law, Actinogen and all of its representatives, directors, officers, partners, employees or professional advisers (**Parties**) exclude all direct and indirect liability arising out of or in connection with any use or reliance of the information contained or described within this presentation. Other than to the extent required by law (and only to that extent), the Parties do not make any representation or give any assurance, guarantee or warranty (express or implied) as to, nor assume any responsibility or liability for, the authenticity, origin, validity, accuracy, suitability or completeness of, or any errors in or omissions from, any information, statement or opinion contained in this presentation or any accompanying, previous or subsequent material or presentation.

Appendix A:
Corporate background

Corporate overview ASX:ACW

Actinogen is an ASX-listed biotech company focused on innovative approaches to treating cognitive impairment associated with neurological and metabolic diseases

Trading metrics

Share price (12 October 2020)	**A$0.028**
No. of shares	1,116.2m
Market cap.	**A$31.3m**
Net cash	A$5.0m
Enterprise Value	**A$26.3m**

Key shareholding metrics



Share price performance



1. As at 30 June 2020

Board of Directors

Commercially experienced and globally recognised leadership team with decades of experience in drug development and biotech investment

Dr. Geoff Brooke

Chairman

- **30+ years experience** in the healthcare investment industry
- Founder and MD of Medvest Inc and GBS Venture Partners
- Significant expertise in biotech: development strategy, capital raising and investments
- MBBS (University of Melbourne); MBA (IMEDE, Switzerland)

Dr. Bill Ketelbey

CEO & MD

- **30+ years experience** in healthcare, biotech and pharmaceutical industries
- Formerly senior international roles at Pfizer; Director at the Westmead Institute of Medical Research
- Involved in clinical development and commercialisation of Aricept™
- MBBCh (University of Witwatersrand); FFPM; MBA (Macquarie); GAICD

Dr. George Morstyn

Non-executive director

- **25+ years experience** in biotech investment and drug development
- Board member of Cancer Therapeutics, Symbio and Biomedvic; Former Senior VP and CMO at Amgen
- Global responsibility for Amgen's drug development in all therapeutic areas
- MBBS (Monash University); PhD (Walter and Eliza Hall Institute); FRACP; MAICD

Mr. Malcolm McComas

Non-executive director

- **25+ years experience** in the financial services industry
- Chairman of Pharmaxis and Fitzroy River Corporation; previously senior leadership roles in investment banking
- Extensive experience in corporate finance, M&A, debt and equity funding transactions across multiple sectors
- BEc, LLB (Monash University); FAICD; SF Fin

Actinogen Medical

Advisory Boards

World-leading, premier academics involved in the development of Xanamem

Xanamem Clinical Advisory Board

Positions Xanamem at the forefront of drug development

Prof. Craig Ritchie
Chair

- World-leading authority on dementia; senior investigator on 30+ drug trials
- Chair of the Scottish Dementia Research Consortium; Professor of the Psychiatry of Ageing' Director of the Centre for Dementia Prevention (University of Edinburgh)

THE UNIVERSITY of EDINBURGH

Prof. Colin Masters
AO

- **35+ years research** on Alzheimer's disease and other neurodegenerative diseases
- Laureate Professor of Dementia Research and Head, Neurodegeneration Division at The Florey Institute (UniMelb)

THE FLOREY
THE UNIVERSITY OF MELBOURNE
The Royal Melbourne Hospital

Prof. Jeffrey Cummings

- World-renowned Alzheimer's researcher and leader of clinical trials
- MD, ScD; Founding Director of the Cleveland Clinic Lou Ruvo Center for Brain Health
- Recognised for this work through various awards

Cleveland Clinic

Scientific Advisory Board

Combining deep understanding of endocrinology, 11β-HSD1 and drug discovery

Prof. Alan Boyd

- **30+ years experience** in the pharmaceutical industry, with senior management roles
- Experience supporting early-stage life-science companies through Boyd Consultants
- Faculty of Pharmaceutical Medicine President, Royal College of Physicians, UK

BOYDS

Prof. Jonathan Seckl

- **Undertaken extensive research** in endocrinology
- Senior VP at the university of Edinburgh; Chaired Panels for MRC, Innovate UK and Wellcome Trust
- MBBS UCL, PhD (London)

THE UNIVERSITY of EDINBURGH

Prof. Brian Walker

- **20+ years research** in the area of disease
- Extensive experience advising for pharmaceutical R&D
- Pro Vice Chancellor for Research Strategy & Resources at Newcastle University, UK

Newcastle University

Prof. Scott Webster

- Chair of Medicines at the Centre of Cardiovascular Science, University of Edinburgh
- Former positions across both biotech and academia
- Founder and Chief Scientific Officer at Kynos Therapeutics

THE UNIVERSITY of EDINBURGH

Actinogen Medical

IP protection

Actinogen maintains a broad composition of matter patent estate, with key patents granted in all major target markets, and new patent applications filed or in development

Patent overview



- Actinogen's patent portfolio **covers a broad range of neurological and metabolic diseases** including Alzheimer's disease
- Xanamem **patents granted in key markets** that account for over 90% of the global pharmaceuticals market
- **Additional patents and patent extensions being actively prosecuted**

>90% of the global Alzheimer's disease and FXS markets

Actinogen Medical

Appendix B:
Other clinical development opportunities

Cognitive impairment associated with schizophrenia

Cognitive impairment can be a debilitating feature of schizophrenia, with no targeted treatments available representing a significant unmet medical need

Schizophenia	▪ Schizophrenia is a complex and chronic mental health disorder that has increasingly been recognized as a cluster of different disorders
Cognitive impairment in schizophrenia	▪ **Cognitive impairment is one of the most debilitating negative symptoms** in schizophrenia, affecting **~75% of patients**[1] ▪ Associated with poor treatment outcomes and patient reintegration into society - a major issue with ongoing patient management ▪ Potentially **a side-effect of current anti-psychotic therapy** (used to treat schizophrenia positive symptoms)
Scientific rationale	▪ **Good scientific rationale for cortisol** as a therapeutic target

[1] Based on consensus Wall Street analyst research reports

Actinogen Medical

Cognitive impairment associated with diabetes

Diabetics are at increased risk of developing cognitive impairment and Alzheimer's disease

At-risk population	▪ Elderly diabetics **have double the risk of developing cognitive impairment and dementia** over a non-diabetic population ▪ **Diabetics often present with chronically raised cortisol,** a risk factor for developing Alzheimer's disease
High Prevalence	▪ The American Diabetes Association currently estimates **14.3 million diabetics >65yrs (26.8% of the senior population) in the US**[1]
Scientific rationale	▪ **Clinical trial (Sandeep, 2004**[2]**; Edinburgh) in this population demonstrated a pro-cognitive effect of 11β-HSD1 inhibition** ▪ **Pro-cognitive efficacy of Xanamem** 20mg daily demonstrated in healthy elderly volunteers in XanaHES, some of which had T2DM[3]

Actinogen evaluating feasibility of new study, given strong likelihood of successfully demonstrating a similar pro-cognitive effect (seen in XanaHES) of Xanamem in an elderly diabetic population

Actinogen Medical

1. Statistics About Diabetes, American Diabetes Association [online: https://www.diabetes.org/resources/statistics/statistics-about-diabetes]
2. Sandeep et al., 2004, PNAS, 101(17):6734-6739
3. T2DM – Type 2 diabetes mellitus